Diagnostic Role of Antiphospholipid Antibodies & Microparticles in Immune

Status Not yet recruiting

Clinical Trial Summary

Identify the procoagulant profile in immune thrombocytopenic patients with thrombosis. Clinical implications of antiphospholipid antibodies in ITP patients with thrombosis. Diagnostic role of microparticles in ITP patients with thrombosis.

Clinical Trial Description

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia and an increased risk of bleeding. Paradoxically, ITP is also associated with an increased risk of thrombosis (1). Recent studies showed that the occurrence of thrombosis in patients with ITP is not purely accidental and can be considered a clinical reality with an important impact on the management of the disease (2). The pathophysiological mechanism for thrombosis in ITP remains unclear. Sever bleeding episodes are relatively rare in some patients with ITP although having low platelet count, suggests that these patients may have a protective factor against bleeding (3). Antiphospholipid (aPL) antibodies are a heterogeneous group of autoantibodies with high affinity for phospholipids such lupus anticoagulant (LA), β2glycoprotien І (β2GPІ), and anticardiolipin (anti-CL). They interfere with physiological mechanisms of coagulation and fibrinolysis, leading the haemostatic balance towards coagulation. Moreover, it seems to affect the physiological function of various cells such as platelets and endothelial cells (4). Microparticles (MPs) are a diverse group of bioactive small-sized vesicles (100-1000nm) that can be found in body fluids and blood after activation, necrosis, or apoptosis of almost all cells. Although most MPs in human blood originate from platelets, MPs are also released from leukocytes, erythrocytes, endothelial cells, smooth muscle cells and cancer cells (5). They participate in intercellular communication and play a major role in homeostasis under physiological conditions and also in diseases (6). The most prominent property of MPs is their procoagulant potential, mainly based on phosphatidylserine exposure and tissue factor expression (7). Elevated levels of antiphospholipid antibodies and microparticles have been reported as a risk for development of prothrombotic state (8). ;

Study Design

Related Conditions & MeSH terms

Thrombosis

Clinical Trial Details

NCT number	NCT05830916
Study type	Observational
Source	Assiut University
Contact	Sarah Omer Nagi, Assiatant lecturer
Phone	01153399098
Email	sarah_med99@yahoo.com
Status	Not yet recruiting
Phase
Start date	September 2024
Completion date	September 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03826043` - THrombo-Embolic Event in Onco-hematology	N/A
Recruiting	`NCT04398628` - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed	`NCT05426564` - Exploratory Assessment of the Quantra® System in Adult ECMO Patients
Recruiting	`NCT02972385` - Pharmacogenomics of Warfarin in Hispanics and Latinos
Completed	`NCT02917213` - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed	`NCT02526628` - Thrombosis and Neurocognition in Klinefelter Syndrome
Completed	`NCT02439190` - CV004-007 Thrombosis Chamber Study	Phase 1
Completed	`NCT02341638` - Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects	Phase 1
Completed	`NCT01855516` - Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin	N/A
Unknown status	`NCT00983112` - Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery	Phase 4
Completed	`NCT00412464` - Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis	Phase 1
Completed	`NCT00346424` - Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters	Phase 3
Completed	`NCT00479362` - Anticoagulant Therapy During Pacemaker Implantation	Phase 4
Completed	`NCT00143715` - Oral Vitamin K for Warfarin Associated Coagulopathy	Phase 3
Terminated	`NCT00303420` - Alteplase for Blood Flow Restoration in Hemodialysis Catheters	Phase 4
Completed	`NCT00039858` - Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin	Phase 4
Completed	`NCT00007410` - Genetic Architecture of Plasma T-PA and PAI-1	N/A
Completed	`NCT00000538` - Dietary Effects on Lipoproteins and Thrombogenic Activity	Phase 3
Completed	`NCT00005436` - Lupus Cohort--Thrombotic Events and Coronary Artery Disease	N/A
Completed	`NCT00000466` - Postmenopausal Estrogen/Progestin Interventions (PEPI)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Diagnostic Role of Antiphospholipid Antibodies and Microparticles in Immune Thrombocytopenic Patients With Thrombosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms